Episurf — Regulatory Filings 2021

Jan 14, 2021

New patent approval in Hong Kong for Episurf Medical

The Intellectual Property Department (IPD) of Hong Kong has announced its intention to grant another patent for Episurf Medical (NASDAQ: EPIS B). The patent, entitled "Method and node for manufacturing a surgical kit for cartilage repair", covers a medical image segmentation process for 3Dvisualisation of anatomical joints. Image segmentation is a part of the technology around Episurf Medical's individualised joint implants and surgical instruments.

"This patent covers important details of the imaging process that forms the basis for the company's Episealer® technology, and we are happy to get improved IP protection in this for us very interesting market", says Katarina Flodström, COO, Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical Tel:+46 (0) 709 62 36 69 Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's μiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on January 14, 2021.